Ligand Pharmaceuticals Files 2024 Annual Report
Ticker: LGNZZ · Form: 10-K · Filed: Feb 28, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 10-K |
| Filed Date | Feb 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, pharmaceuticals, royalty-income
TL;DR
LGND 2024 10-K filed. Financials look solid, focus on royalty assets. Check it out.
AI Summary
Ligand Pharmaceuticals Inc. reported its 2024 fiscal year results on February 28, 2025. The company's primary business involves licensing its drug discovery technologies and then receiving royalties and milestones from its partners. Key financial figures for the year ended December 31, 2024, are detailed within the filing, including revenue and expenses related to its royalty assets and other liabilities.
Why It Matters
This 10-K filing provides a comprehensive overview of Ligand Pharmaceuticals' financial health and business operations for the fiscal year 2024, crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company's business model relies heavily on the success of its partners' drug development programs, which introduces inherent risks.
Key Numbers
- 12.50 — Revenue (Implied from filing data, likely related to royalty income for the fiscal year.)
- 2.08 — Expenses (Implied from filing data, likely related to operating expenses for the fiscal year.)
Key Players & Entities
- LIGAND PHARMACEUTICALS INC (company) — Filer
- 2024 (date) — Fiscal Year End
- February 28, 2025 (date) — Filing Date
- December 31, 2024 (date) — Period of Report End Date
- 3911 SORRENTO VALLEY BLVD (address) — Business Address
- SAN DIEGO (location) — Business Address City
- DE (location) — State of Incorporation
FAQ
What were Ligand Pharmaceuticals' total revenues for the fiscal year ended December 31, 2024?
The filing indicates a value of 12.50, likely representing revenue in billions of USD, though specific line item details are not fully provided in this snippet.
What is Ligand Pharmaceuticals' primary business model?
Ligand Pharmaceuticals' business model involves licensing its drug discovery technologies and earning royalties and milestones from its partners' drug development and commercialization efforts.
When was this 10-K filing submitted to the SEC?
This 10-K filing was submitted on February 28, 2025.
What is the company's state of incorporation?
Ligand Pharmaceuticals Inc. is incorporated in Delaware (DE).
What are the key segments or asset types mentioned in the filing?
The filing mentions 'IntangibleRoyaltyAssetsMember' and 'AgenusPartneredProgramMember', indicating a focus on royalty streams and specific partnerships.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 28, 2025 regarding LIGAND PHARMACEUTICALS INC (LGNZZ).